Analyst Price Target is $25.50
▲ +618.31% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Achieve Life Sciences in the last 3 months. The average price target is $25.50, with a high forecast of $27.00 and a low forecast of $24.00. The average price target represents a 618.31% upside from the last price of $3.55.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Achieve Life Sciences. This Buy consensus rating has held steady for over two years.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.